- Home
- SBS vs ITCI Comparison
SBS vs ITCI Comparison
Compare SBS & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBS
- ITCI
- Stock Information
- Founded
- SBS 1954
- ITCI 2002
- Country
- SBS Brazil
- ITCI United States
- Employees
- SBS N/A
- ITCI N/A
- Industry
- SBS Water Supply
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- SBS Utilities
- ITCI Health Care
- Exchange
- SBS Nasdaq
- ITCI Nasdaq
- Market Cap
- SBS 11.6B
- ITCI 13.5B
- IPO Year
- SBS 2002
- ITCI N/A
- Fundamental
- Price
- SBS $17.96
- ITCI $131.81
- Analyst Decision
- SBS
- ITCI Buy
- Analyst Count
- SBS 0
- ITCI 13
- Target Price
- SBS N/A
- ITCI $106.58
- AVG Volume (30 Days)
- SBS 975.0K
- ITCI 2.0M
- Earning Date
- SBS 03-24-2025
- ITCI 05-06-2025
- Dividend Yield
- SBS 1.18%
- ITCI N/A
- EPS Growth
- SBS 171.87
- ITCI N/A
- EPS
- SBS 2.27
- ITCI N/A
- Revenue
- SBS $5,844,148,990.00
- ITCI $680,852,000.00
- Revenue This Year
- SBS N/A
- ITCI $40.64
- Revenue Next Year
- SBS $14.85
- ITCI $58.53
- P/E Ratio
- SBS $8.00
- ITCI N/A
- Revenue Growth
- SBS 41.35
- ITCI 46.62
- 52 Week Low
- SBS $13.10
- ITCI $64.09
- 52 Week High
- SBS $18.36
- ITCI $131.87
- Technical
- Relative Strength Index (RSI)
- SBS 61.75
- ITCI 85.59
- Support Level
- SBS $17.13
- ITCI $131.19
- Resistance Level
- SBS $18.16
- ITCI $131.79
- Average True Range (ATR)
- SBS 0.39
- ITCI 0.13
- MACD
- SBS 0.06
- ITCI -0.41
- Stochastic Oscillator
- SBS 87.68
- ITCI 91.18
About SBS Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (Each repstg 250)
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.